The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
The firm said its test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost, and labor.
The company said it intends to pursue Emergency Use Authorization from the US Food and Drug Administration for the test and that it is planning an IPO.